A Single-arm, Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Cretostimogene Grenadenorepvec in Patients With BCG-unresponsive High-risk Non-Muscle Invasive Bladder Cancer
Latest Information Update: 02 Feb 2026
At a glance
- Drugs Cretostimogene grenadenorepvec (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Sponsors Lepu Biopharma
Most Recent Events
- 21 Dec 2025 New trial record